Skip to main content

Table 2 Medication classes by treatment line among those receiving anti-cancer treatment in the advanced stage ovarian cancer cohort (n=8,325)

From: A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer

 

N (%)

N (%)

N (%)

N (%)

N (%)

All Lines (All treated patients)

First Line

Second Line

Third Line

Fourth Line or Higher

Total cancer treatment episodes with treatment lines observed, among incident cases, N (%)a,b,c,d

8325 (100%)

8325 (100%)

5335 (64.1%)

3711 (44.6%)

2487 (29.9%)

Alkylating Agents

5863 (70.43%)

5071 (60.91%)

2425 (45.45%)

1230 (33.14%)

1074 (43.18%)

 Carboplatin (platinum agent)

5055 (60.72%)

4243 (50.97%)

1926 (36.10%)

890 (23.98%)

819 (32.93%)

 Cisplatin (platinum agent)

1075 (12.91%)

546 (6.56%)

368 (6.90%)

257 (6.93%)

258 (10.37%)

 Cyclophosphamide

358 (4.30%)

122 (1.47%)

77 (1.44%)

68 (1.83%)

160 (6.43%)

 Ifosfamide/Mesna

44 (0.53%)

15 (0.18%)

14 (0.26%)

10 (0.27%)

17 (0.68%)

 Ifosfamide

39 (0.47%)

13 (0.16%)

13 (0.24%)

10 (0.27%)

16 (0.64%)

 Altretamine

17 (0.20%)

≤10

≤10

≤10

12 (0.48%)

 Melphalan

≤10

0 (0%)

0 (0%)

≤10

≤10

 Oxaliplatin (platinum agent)

327 (3.93%)

207 (2.49%)

117 (2.19%)

65 (1.75%)

72 (2.90%)

Mitotic Inhibitors

5368 (64.48%)

4584 (55.06%)

2033 (38.11%)

975 (26.27%)

904 (36.35%)

 Paclitaxel (Taxane)

4892 (58.76%)

4160 (49.97%)

1734 (32.50%)

807 (21.75%)

715 (28.75%)

 Albumin bound paclitaxel

3506 (42.11%)

2888 (34.69%)

1182 (22.16%)

540 (14.55%)

543 (21.83%)

 Docetaxel (Taxane)

864 (10.38%)

533 (6.40%)

310 (5.81%)

155 (4.18%)

185 (7.44%)

 Vinorelbine

123 (1.48%)

18 (0.22%)

30 (0.56%)

31 (0.84%)

80 (3.22%)

Antimetabolites

2045 (24.56%)

799 (9.60%)

737 (13.81%)

558 (15.04%)

894 (35.95%)

 Gemcitabine

1416 (17.01%)

363 (4.36%)

413 (7.74%)

345 (9.30%)

651 (26.18%)

 Capecitabine

219 (2.63%)

86 (1.03%)

87 (1.63%)

55 (1.48%)

89 (3.58%)

 Pemetrexed

247 (2.97%)

46 (0.55%)

39 (0.73%)

41 (1.10%)

164 (6.59%)

Antineoplastic - Angiogenesis Inhibitors

1572 (18.88%)

524 (6.29%)

482 (9.03%)

429 (11.56%)

716 (28.79%)

 Bevacizumab

1567 (18.82%)

524 (6.29%)

481 (9.02%)

427 (11.51%)

712 (28.63%)

Antineoplastic - Hormonal and Related Agents

3102 (37.26%)

2095 (25.17%)

1679 (31.47%)

1146 (30.88%)

1148 (46.16%)

 Anastrozole

437 (5.25%)

177 (2.13%)

170 (3.19%)

111 (2.99%)

176 (7.08%)

 Letrozole

354 (4.25%)

103 (1.24%)

130 (2.44%)

97 (2.61%)

173 (6.96%)

 Exemestane

127 (1.53%)

41 (0.49%)

45 (0.84%)

43 (1.16%)

49 (1.97%)

 Leuprolide

45 (0.54%)

20 (0.24%)

17 (0.32%)

15 (0.40%)

23 (0.92%)

 Goserelin

10 (0.12%)

≤10

≤10

≤10

≤10

 Triptorelin

≤10

0 (0%)

0 (0%)

0 (0%)

≤10

 Tamoxifen

425 (5.11%)

167 (2.01%)

150 (2.81%)

98 (2.64%)

153 (6.15%)

Antineoplastics Misc.

≤10

≤10

≤10

≤10

≤10

Topoisomerase I/II Inhibitors

1024 (12.30%)

292 (3.51%)

284 (5.32%)

257 (6.93%)

527 (21.19%)

 Topotecan

691 (8.30%)

104 (1.25%)

162 (3.04%)

179 (4.82%)

406 (16.32%)

 Irinotecan

220 (2.64%)

93 (1.12%)

78 (1.46%)

58 (1.56%)

99 (3.98%)

 Etoposide

184 (2.21%)

95 (1.14%)

46 (0.86%)

20 (0.54%)

61 (2.45%)

Antineoplastic - Antibodies

1684 (20.23%)

608 (7.30%)

537 (10.07%)

464 (12.50%)

744 (29.92%)

Antineoplastic Combinations

≤10

0 (0%)

≤10

≤10

≤10

Chemotherapy Rescue/Antidote Agents

340 (4.08%)

242 (2.91%)

159 (2.98%)

90 (2.43%)

91 (3.66%)

 Leucovorin

328 (3.94%)

239 (2.87%)

155 (2.91%)

87 (2.34%)

85 (3.42%)

Somatostatin

83 (1%)

28 (0.34%)

24 (0.45%)

26 (0.70%)

32 (1.29%)

Doxorubicin (Anthracycline)

1789 (21.49%)

418 (5.02%)

536 (10.05%)

485 (13.07%)

726 (29.19%)

Antineoplastic Antibiotics

1848 (22.20%)

468 (5.62%)

548 (10.27%)

488 (13.15%)

735 (29.55%)

Antineoplastic - Hedgehog Pathway Inhibitors

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Antineoplastic – Immunomodulators

≤10

≤10

0 (0%)

0 (0%)

0 (0%)

Antineoplastic Radiopharmaceuticals

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Chemotherapy Adjuncts

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Immune-Checkpoint Inhibitors

63 (0.76%)

15 (0.18%)

16 (0.30%)

11 (0.30%)

35 (1.41%)

 Nivolumab

35 (0.42%)

≤10

12 (0.22%)

≤10

19 (0.76%)

 Pembrolizumab

21 (0.25%)

≤10

≤10

≤10

15 (0.60%)

 Atezolizumab

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Avelumab

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Ipilimumab

11 (0.13%)

≤10

≤10

≤10

≤10

 Durvalumab

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Antineoplastic Enzyme Inhibitors/PARP inhibitors

572 (6.87%)

274 (3.29%)

196 (3.67%)

120 (3.23%)

209 (8.40%)

 Olaparib

83 (1%)

≤10

9 (0.17%)

12 (0.32%)

66 (2.65%)

 Rucaparib

23 (0.28%)

0 (0%)

≤10

≤10

21 (0.84%)

 Niraparib

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Pazopanib

32 (0.38%)

≤10

≤10

≤10

13 (0.52%)

  1. Abbreviations: N Number, Misc. Miscellaneous
  2. a The cohort includes patients who had at least one ICD-9-CM or ICD-10 diagnosis code for ovarian cancer, were continuously enrolled in a health plan contributing data to the HIRD for at least six months, and were confirmed to have advanced ovarian cancer based on staging information from either a cancer registry or the HIRE Oncology data or met the predictive model algorithm for advanced stage ovarian cancer. Patients may have received multiple treatments during each treatment line and may have received cancer treatment prior to line 1 if they were dispensed prior to the advanced stage ovarian index date. Diagnoses are not linked to a specific prescription, and thus some of the record treatments may have been specified for other cancers, if a patient had multiple malignancies.
  3. bIncident cases are individuals for whom at least six months of data were available in the HIRD prior to the first diagnosis of ovarian cancer in claims.
  4. cStratum percentages based on total number of cases for all lines.
  5. dPatients with follow-up periods shorter than 28 days (specified segment length) were excluded from the treatment line related analyses.
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us